900019-52-5

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl-4-amino-3-bromo-5-methylbenzoate is used as an intermediate in the synthesis of pharmaceuticals for its unique structural features that can be further modified to create various medicinal compounds.
Used in Agrochemical Production:
Methyl-4-amino-3-bromo-5-methylbenzoate is also utilized in the production of agrochemicals, where its specific chemical properties can be harnessed to develop new pesticides or herbicides.
Used in Organic Chemistry Research:
Methyl-4-amino-3-bromo-5-methylbenzoate serves as a valuable compound in organic chemistry research, where it can be used to explore new reactions, mechanisms, and the synthesis of novel organic compounds.

Upstream product

• 18595-14-7 methyl 4-amino-3-methylbenzoate 

Downstream Products

• 1427460-96-5 methyl 7-bromo-1H-indazole-5-carboxylate 

Relevant academic research and scientific papers

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors

A series of novel small-molecule pan-genotypic hepatitis C virus (HCV) NS5A inhibitors with picomolar activity containing 2-[(2S)-pyrrolidin-2-yl]-5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}buta-1,3-diyn-1-yl)phenyl]-1H-imidazole core was designed based on molecular modeling study and SAR analysis. The constructed in silico model and docking study provide a deep insight into the binding mode of this type of NS5A inhibitors. Based on the predicted binding interface we have prioritized the most crucial diversity points responsible for improving antiviral activity. The synthesized molecules were tested in a cell-based assay, and compound 1.12 showed an EC50 value in the range of 2.9–34 pM against six genotypes of NS5A HCV, including gT3a, and demonstrated favorable pharmacokinetic profile in rats. This lead compound can be considered as an attractive candidate for further clinical evaluation.

PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS.

Compound represented by formula 1 : or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: where R11 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy, and arrows (1-C4alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (— ) indicate the position of substituents attachment.

SELECTIVE HDAC1 AND HDAC2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.